This headline scares us:

According to the Wall Street Journal, the “deal” would require “drugmakers Eli Lilly and Novo Nordisk to allow the lowest doses of some of their obesity drugs to be sold to consumers at $149 for a month’s supply via TrumpRx.”

No, no, no. A thousand times NO!

We love the idea of allowing manufacturers to sell direct-to-patients and have supported regulatory changes to allow a direct sales channel to compete with insurance/pharmacy sales. But in a free market, buyers and sellers set prices, not politicians. If drug makers believe that this or any administration will set floors on their prices, the amount of investment dollars for finding cures will start to dry up.

This is a short term gain for a lot of long term pain.